Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Resection

This study tests whether a personalized cancer vaccine combined with a chemotherapy pill (capecitabine) can prevent intrahepatic cholangiocarcinoma (bile duct cancer inside the liver) from coming back after surgery. The vaccine targets specific mutations unique to each patient's tumor. **You may be eligible if...** - You are 18 to 75 years old - You had surgery to remove bile duct cancer inside the liver (intrahepatic cholangiocarcinoma) - Your surgery showed high-risk features such as positive margins, lymph node involvement, large tumor size, or vascular invasion - Your liver function is good (Child-Pugh A, ECOG 0–1) - You have not yet started systemic therapy after surgery **You may NOT be eligible if...** - You received treatment before surgery (neoadjuvant therapy) - You already started post-surgery systemic treatment - You have active hepatitis B with detectable viral levels Talk to your doctor to see if this trial is right for you.